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Abstract
Adenosine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Adenosine Receptors
[103]) are activated by the endogenous ligand adenosine (potentially inosine also at A3 receptors). Crystal
structures for the antagonist-bound [146, 305, 213, 55], agonist-bound [362, 196, 198] and G protein-bound A2A
adenosine receptors [43] have been described. The structures of an antagonist-bound A1 receptor [123] and an
adenosine-bound A1 receptor-Gi complex [80] have been resolved by cryo-electronmicroscopy. Another
structure of an antagonist-bound A1 receptor obtained with X-ray crystallography has also been reported [51].
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